PensionDanmark Pensionsforsikringsaktieselskab Has $10.71 Million Position in Becton, Dickinson and Company $BDX

Key Points

• PensionDanmark reduced its Becton, Dickinson and Company stake by 9% in the second quarter, selling 7,017 shares and retaining 70,781 shares valued at approximately $10.71 million. Institutional investors collectively own 86.97% of BDX.
• BDX exceeded quarterly expectations, reporting $4.98 billion in revenue and adjusted EPS of $3.23, while revenue rose 5.4% year over year. The company raised its fiscal 2026 adjusted EPS outlook to $12.62–$12.72.
• Analyst sentiment remains mixed: several firms raised price targets, but the consensus rating is “Hold” with an average target of $185. Shares opened at $176.53, while profitability concerns persisted as quarterly EPS declined from $3.68 a year earlier.

PensionDanmark Pensionsforsikringsaktieselskab cut its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,781 shares of the medical instruments supplier's stock after selling 7,017 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab's holdings in Becton, Dickinson and Company were worth $10,711,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC lifted its holdings in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock worth $1,827,000 after purchasing an additional 1,354 shares during the last quarter. United Bank boosted its stake in Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock valued at $887,000 after purchasing an additional 993 shares during the period. Marshall Wace LLP grew its holdings in Becton, Dickinson and Company by 365.1% in the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock valued at $5,491,000 after buying an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC increased its position in Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock worth $4,048,000 after buying an additional 6,058 shares during the period. Institutional investors own 86.97% of the company's stock.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Quarterly results beat estimates. Fiscal Q3 revenue rose 5.4% year over year to approximately $5.0 billion, exceeding the $4.89 billion consensus estimate. Adjusted EPS of $3.23 also surpassed expectations of $3.14, with growth across BD’s core medical and interventional businesses. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD raised its fiscal 2026 outlook. The company now expects adjusted EPS of $12.62 to $12.72, above the prior outlook and the roughly $12.56 analyst consensus. Management also expects revenue growth toward the high end of its range and is targeting 90% free-cash-flow conversion. Year-to-date operating cash flow increased 33.3% to $2.1 billion, while free cash flow rose 44.6% to $1.7 billion. BD raises FY 2026 adjusted EPS guidance
• Positive Sentiment: Citigroup became more bullish. Citi raised its price target from $198 to $204 and assigned a “buy” rating, implying meaningful upside based on the cited reference price.
• Neutral Sentiment: Analyst views remain divided. Piper Sandler lifted its target to $175 but maintained a “neutral” rating, while Wells Fargo raised its target to $170 and kept an “equal weight” rating. Both targets remain below the cited share price, limiting the positive impact of the revisions.
• Negative Sentiment: Margins and earnings comparisons are concerns. Although revenue and adjusted earnings beat forecasts, margins declined and adjusted EPS fell from $3.68 in the year-earlier quarter. The stock’s elevated valuation may also make investors more sensitive to profitability pressure.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BDX. Barclays lifted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Zacks Research raised shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research report on Friday, April 10th. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Friday. The Goldman Sachs Group cut their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a report on Wednesday, May 27th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $185.00.

Becton, Dickinson and Company Stock Performance

BDX opened at $176.53 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.55 and a current ratio of 0.87. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The firm has a market cap of $48.64 billion, a P/E ratio of 53.17, a price-to-earnings-growth ratio of 12.53 and a beta of 0.19. The business's fifty day moving average is $154.37 and its 200-day moving average is $162.51.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company's payout ratio is presently 106.33%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business's stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source